A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment failure during the first year. We previously demonstrated that prolonged early G1 cell cycle arrest induced by the oral, specific CDK4/6 inhibito...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Martin, Peter, Bartlett, Nancy L., Blum, Kristie A., Park, Steven, Maddocks, Kami, Ruan, Jia, Ridling, LeAnn, Dittus, Christopher, Chen, Zhengming, Huang, Xiangao, Inghirami, Giorgio, DiLiberto, Maurizio, Chen-Kiang, Selina, Leonard, John P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6418474/
https://ncbi.nlm.nih.gov/pubmed/30692121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-11-886457
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados